Generex Biotech: A Breath of Fresh Insulin - Biotech Boldman

Sign Up | Log In | What is SocialPicks?

Generex Biotech: A Breath of Fresh Insulin
Apr 14, 2008 07:38 AM UTC

Biotech Boldman

Return	Risk
-52.94%	MID

Tracked Blogger

Profile & Performance

Subscribe to author

Symbol	Sentiment	Start	Return	Closed
GNBT		04/14/08	-52.94%	--

Via Long Investment Ideas from Seeking Alpha:

As a diabetic and as a former co-manager for an offshore private wealth fund, I have long-followed the diabetic drug market, the large pharmas, and the small-cap biotech companies in that space. The global diabetes market affects approximately 246 million people worldwide and this number is increasing. The World Health Organization projects that diabetics will increase to 300 million by 2011. And, the International Diabetes Federation predicts 380 million diabetics by 2025.

The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. There are many companies hoping to capture a portion of that rapidly expanding market.

Read the rest of original post »

Comments (1)

Add Comment

taldrkhandsme2003

N/A

1 point commented 542 days ago reply

Furture more, the broader segment of diabetics and their support groups have never heard of this new delivery system for insulin. I firmly believe that when this product is featured in a news story on a major network, that the American investment community will go crazy for it. At least temporarily, until the cost of Oral-lyn keeps it off of the drug list for major insurers in favor of much cheaper insulin delivery systems. I also believe that, in time, insurance providers will succumb to public and government pressure to include this more comfortable method of insulin delivery in the covered drugs portion of their policies. I worked on the Exubera project as a clinical research monitor and I can tell you that the excitement over an alternative to needles can not be over estimated.

Your Comment

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.